...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes, obesity & metabolism >A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment
【24h】

A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment

机译：治疗24周后，长效和短效GLP-1受体激动剂（塔斯普鲁肽每周一次，艾塞那肽每天两次）的直接比较

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims: T-emerge 2 was a randomized, open-label, 24-week trial comparing subcutaneous taspoglutide 10mg weekly (Taspo10), taspoglutide 20mg weekly (Taspo20; titrated after 4weeks of Taspo10), with exenatide 10 mcg BID (Exe; after 4weeks of Exe 5 mcg) in patients inadequately controlled on metformin, a thiazolidinedione, or both. T-emerge 2 showed that once-weekly Taspo provided better glycaemic control than Exe. This report focuses on a subset of T-emerge 2 participants undergoing a standardized liquid meal comparing Taspo to Exe, which has been previously shown to lower postprandial glucose. Methods: Meal tolerance tests (MTT) were performed at baseline and at week 24 in a subset of Taspo10, Taspo20 and Exe patients (n=42, 39 and 67, respectively). Blood samples for glucose, insulin, glucagon and C-peptide were obtained before and after (30, 60, 90, 120 and 180min) ingestion of a standardized liquid meal. Results: The 2-h postprandial, mean 0-3h and iAUC0-3h glucose during the MTT was reduced to a similar extent in all groups and the time profile of the postprandial glucose showed a similar pattern. Taspo10 and Taspo20, but not Exe, significantly increased insulin from baseline (both mean and iAUC0-3h). Although changes from baseline in C-peptide were not significant within any treatment group, the mean change from baseline (both mean 0-3h and iAUC0-3h) was significantly increased in Taspo10 vs. Exe. Mean glucagon showed significant decreases in all groups. Conclusion: Taspoglutide and Exe improved postprandial glucose tolerance to a similar extent but possibly with different intimate mechanisms.
机译：目的：T-emerge 2是一项随机的，开放标签的，为期24周的试验，比较了每周皮下注射taspoglutide（Taspo10），taspoglutide每周20mg（Taspo20;在Taspo10注射4周后滴定）与艾塞那肽10 mcg BID（Exe;在注射4周后）实施例5 mcg）的患者对二甲双胍，噻唑烷二酮或两者控制不佳。 T-emerge 2显示，Taspo每周一次提供比Exe更好的血糖控制。本报告重点关注正在进行标准化流质餐的T-emerge 2参与者的一部分，该餐点将Taspo与Exe进行了比较，以前已证明其可降低餐后血糖。方法：在Taspo10，Taspo20和Exe患者（分别为n = 42、39和67）的亚组中，在基线和第24周进行了膳食耐受性测试（MTT）。在摄入标准化液体餐之前和之后（30、60、90、120和180分钟）获取葡萄糖，胰岛素，胰高血糖素和C肽的血样。结果：各组MTT的餐后2 h血糖，平均0-3h和iAUC0-3h葡萄糖均降低了相似的程度，并且餐后葡萄糖的时间曲线显示出相似的模式。 Taspo10和Taspo20（而非Exe）从基线开始显着增加胰岛素（均值和iAUC0-3h）。尽管在任何治疗组中C肽相对于基线的变化均不显着，但Taspo10与Exe相比，相对于基线的平均变化（均值为0-3h和iAUC0-3h）明显增加。平均胰高血糖素在所有组中均显示显着降低。结论：Taspoglutide和Exe可以相似程度地改善餐后葡萄糖耐量，但可能具有不同的内在机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号